Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

doi:10.1158/1078-0432.CCR-15-2477

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2016

Telli Melinda L, Timms Kirsten M, Reid Julia, Hennessy Bryan, Mills Gordon B, Jensen Kristin C, Szallasi Zoltan, Barry William T, Winer Eric P, Tung Nadine M, Isakoff Steven J, Ryan Paula D, Greene-Colozzi April, Gutin Alexander, Sangale Zaina, Iliev Diana, Neff Chris, Abkevich Victor, Jones Joshua T, Lanchbury Jerry S, Hartman Anne-Renee, Garber Judy E, Ford James M, Silver Daniel P, Richardson Andrea L

Abstract excerpt

PURPOSE: BRCA1/2-mutated and some sporadic triple-negative breast cancers (TNBC) have DNA repair defects and are sensitive to DNA-damaging therapeutics. Recently, three independent DNA-based measures of genomic instability were developed on the basis of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST). EXPERIMENTAL DESIGN: We assessed a combined homologous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allelic Imbalance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Homologous Recombination

Share to Loss of Heterozygosity

Share to Platinum

Share to Telomere

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26957554
DOI: 10.1158/1078-0432.CCR-15-2477
PMCID: PMC6773427

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.PMID 26957554Read ↗

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.Semantic proximity Read ↗

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.Semantic proximity Read ↗

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancerSemantic proximity Read ↗

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.Semantic proximity Read ↗

A multiomics signature highlights alterations underlying homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Semantic proximity Read ↗

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationSemantic proximity Read ↗

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.Semantic proximity Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.Semantic proximity Read ↗

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugsSemantic proximity Read ↗

Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.